

## Oregon Cardiovascular Symposium Friday, April 17, 2020

7:00 AM	<b>Friday's Sessions will be Posted Online for Viewing</b>
1 Hour	<b>Independent CME Activity — Redefining the Role of Cardiologists in the Management of Type 2 Diabetes: Best Practices for Cardiovascular Risk Reduction — Integrity Continuing Education</b> <i>Darren McGuire, MD, MHSc, UT Southwestern and Julio Rosenstock, MD, Dallas Diabetes Center</i>
1 Hour	<b>Session #1 — Keto, Paleo, Fasting — Oh My? Navigating the Evidence for a Cardioprotective Diet</b> <i>Tracy Severson, RD, LD, OHSU</i>
1 Hour	<b>Session #2 — Shared Decision Making in the Treatment of Cardiac Disease</b> <i>Dan Matlock, MD, MPH, University of Colorado</i>
1 Hour	<b>Session #3 — Novel Strategies Screening for CVD — Genetics, Biomarkers, Imaging, etc.</b> <i>James de Lemos, MD, PhD, UT Southwestern</i>
1 Hour	<b>Independent CME Activity — Dual Antiplatelet Therapy in Coronary Artery Disease: New Guidelines and Beyond — Rockpointe CME</b> <i>L. Kristin Newby, MD, MHS, Duke University</i>
1 Hour	<b>Session #4 — High Sensitivity Troponin, Type 2 NSTEMI, and the Everchanging Definition of Myocardial Infarctions</b> <i>James de Lemos, UT Southwestern</i>
1 Hour	<b>Session #5 — Intersection of Antiplatelet and Anticoagulant Therapy — How to Best Manage Patients Who Need Both?</b> <i>L. Kristin Newby, MD, MHS, Duke University</i>
1 Hour	<b>Session #6 — The Tricuspid Valve — Current Therapies and Updates on Tricuspid Valve Management</b> <i>Vinod Thourani, MD, FACS, FACC, Piedmont Heart Institute</i>

## Oregon Cardiovascular Symposium Saturday, April 18, 2020

7:00 AM	<b>Saturday's Sessions will be Posted Online for Viewing</b>
1 Hour	<b>Independent CME Activity: Mastering the Art of Prior Authorization to Improve Patient Access to PCSK9 Inhibitors — Integrity Continuing Education</b> <i>James Underberg, MS, MD, FACPM, FACP, FNLA, NYU Langone Health</i>
1 Hour	<b>Session #7 — Low and Moderate Risk Severe Aortic Stenosis — How to Develop a 20 - 30 Year Plan — TAVR, SAVR, and Valve in Valve Treatment Strategies</b> <i>Vinod Thourani, MD, FACS, FACC, Piedmont Heart Institute</i>
1 Hour	<b>Session #8 — Role of Biomarkers and Imaging in CVD Prevention</b> <i>Michael Shapiro, DO, FACC, Wake Forest University</i>
1 Hour	<b>Session #9 — Advanced Heart Failure — When to Refer for Advanced Therapies and When to Refer to Hospice</b> <i>James Fang, MD, University of Utah</i>
1 Hour	<b>Session #10 — Cardiovascular Complications of COVID-19</b> <i>Ty Gluckman, MD, FACC, Providence Heart and Vascular</i>
1 Hour	<b>Session #11 — Top 10 Clinical Pearls in Treating Heart Failure</b> <i>James Fang, MD, University of Utah</i>
1 Hour	<b>Session #12 — Surgical and Interventional Left Atrial Appendage Closure — Are We Sure This is Beneficial?</b> <i>Matthew Brennan, MD, MPH, Duke University</i>
1 Hour	<b>Session #13 — Hypertension Guidelines — Debating the Goals</b> <i>Matthew Sorrentino, MD, FACC, FAHA, University of Chicago</i>
1 Hour	<b>Session #14 — Combining Anatomic and Functional Information in the Assessment of CAD — Coronary CTA with Fractional Flow Reserve</b> <i>Maros Ferencik, MD, PhD, OHSU</i>